Search

Displaying results 3031 - 3040 of 6951 in total
  1. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    [A243789, A243794, A243799] The European Commission granted Novavax conditional marketing authorization for nuvaxovid for active immunization to prevent COVID-19 caused by SARS-CoV-2 on December 20, … [L49111] In the fall of 2024, an updated formulation covering the Omicron JN.1 subvariant was approved for use in Canada and the US.[L51394,L51399]

  2. Drug

    Agmatine

    go.drugbank.com/drugs/DB08838
    Experimental

    The exact mechanism of action is still being investigated for all of the potential indications of agmatine. … As an experimental drug, agmatine is being studied for several indications such as cardioprotection, diabetes, decreased kidney function, neuroprotection (stroke, severe CNS injuries, epilepsy, glaucoma

    Categories: NMDA Receptor Antagonists
  3. Drug

    EGEN-001

    go.drugbank.com/drugs/DB05953
    Investigational

    EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity

  4. Drug

    BHV-1310

    go.drugbank.com/drugs/DB22674
    Experimental

    BHV-1310 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.

  5. Drug

    Tafluprost

    go.drugbank.com/drugs/DB08819
    Approved

    Tafluprost was approved for use in the U.S. on February 10, 2012.

    Categories: Prostaglandin Receptor Agonists
  6. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia

  7. Drug

    Trimetrexate

    go.drugbank.com/drugs/DB01157
    Approved

    It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.

  8. Drug

    Ancestim

    go.drugbank.com/drugs/DB09103
    ApprovedWithdrawn

    It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal

  9. Drug

    Raseglurant

    go.drugbank.com/drugs/DB05070
    Investigational

    The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety. … ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).

  10. Drug

    Votucalis

    go.drugbank.com/drugs/DB05032
    Investigational

    rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.